Procurement comparison
Peptide Lab Monitoring Blood Markers Track: Comparison Table
This table maps peptide classes to their required biomarker panels, detailing which markers reveal efficacy, what shifts indicate proper response, and when testing should occur. Growth Hormone Secretagogues (MK 677, CJC1295, Hexarelin) IGF-1, IGFBP-3, fasting
Review the documented criteria directly; this page does not generate a winner or rating.
- This table maps peptide classes to their required biomarker panels, detailing which markers reveal efficacy, what shifts indicate proper response, and when testing should occur.
- Growth Hormone Secretagogues (MK 677, CJC1295, Hexarelin)
- IGF-1, IGFBP-3, fasting glucose, HbA1c
- IGF-1 increase 40–80 ng/mL above baseline; IGFBP-3 proportional rise; glucose stable or <10 mg/dL increase
- Baseline, weeks 4, 8, 12
- Without IGF-1 and IGFBP-3 co-elevation, pituitary response is incomplete. Adjust dose or investigate non-responder status
- Immune-Modulating Peptides (Thymalin, Thymosin Beta-4)
- CBC with differential, CRP, IL-6, TNF-alpha, CD4/CD8 ratio
- CRP reduction >25%, IL-6 and TNF-alpha decline >30%, CD4/CD8 normalisation toward 1.5–2.5
- Baseline, weeks 6, 12
- Cytokine profiles reveal immune reconstitution invisible to symptom tracking. Essential for validating thymic peptide protocols
- Metabolic Peptides (Tesofensine, Survodutide, Mazdutide, Lipo C)
- CMP, lipid panel, TSH/free T3/free T4, fasting insulin, HOMA-IR
- Triglycerides down 20–40%, LDL particle shift toward large buoyant, fasting insulin decline >15%, HOMA-IR improvement
- Lipid and insulin markers prove substrate shift from glucose to fat oxidation. Weight alone misses metabolic improvement
- Neuroprotective Peptides (Cerebrolysin, Dihexa, P21)
- Comprehensive metabolic panel, liver function tests, inflammatory markers
- AST/ALT stable, CRP stable or declining, glucose stable
- Baseline, weeks 4, 12
- Neuropeptides lack direct blood biomarkers. Monitoring focuses on safety (hepatic function) and ruling out inflammatory confounders
- Musculoskeletal Peptides (BPC-157, TB-500, Cartalax)
- CRP, creatine kinase, complete metabolic panel
- CRP reduction correlating with injury resolution, CK elevation resolving within 4–6 weeks post-injury
- Baseline, weeks 2, 6, 12
- CK and CRP track inflammation resolution. Musculoskeletal peptides require injury-specific functional assessments more than biomarkers